High-mobility group box 1 serves as an inflammation driver of cardiovascular disease

Area of Science:

• Cardiovascular Science
• Immunology
• Molecular Biology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality, with inflammation playing a critical role in its pathogenesis.
• High-mobility group box 1 (HMGB1), a nuclear DNA-binding protein, is implicated in activating innate immunity and driving inflammation in CVD.
• HMGB1 is present in cardiac cells and influences various signaling pathways.

Purpose of the Study:

• To elucidate the role of HMGB1 in cardiovascular disease.
• To discuss HMGB1's biological functions, receptors, and signaling pathways.
• To explore HMGB1's contribution to the pathophysiology of various cardiovascular conditions.

Main Methods:

• Literature review and synthesis of existing research on HMGB1.
• Analysis of HMGB1's involvement in inflammatory processes.
• Examination of HMGB1's role in specific cardiovascular pathologies.

Main Results:

• HMGB1 acts as a key mediator of inflammation in the context of CVD.
• HMGB1 binding to its receptors initiates signaling cascades that promote cardiovascular damage.
• HMGB1 is implicated in cardiac remodeling, hypertrophy, myocardial infarction, heart failure, pulmonary hypertension, atherosclerosis, and cardiomyopathy.

Conclusions:

• HMGB1 is a significant contributor to the inflammatory mechanisms underlying cardiovascular diseases.
• Targeting HMGB1 presents a potential therapeutic strategy for managing CVD.
• Further research into HMGB1 pathways is crucial for developing novel CVD treatments.